DRKS00014942Enrolling By Invitation不适用
MESI-STRAT Endocrine Therapy Termination Trial - ET Termination Trial
Stiftung PATH Biobank0 个研究点目标入组 200 人开始时间: 2018年6月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- Female
入选标准
- •sample donation for the PATH Biobank at timepoint of primary surgery, estrogen receptor positive breast cancer, antihormonal therapy reported in follow-up and within the last, fifth year of therapy
排除标准
- •other therapy for BC (breast cancer) than ET ongoing, inflammatory cancers, pregnancy, any medical condition (e.g. substance abuse) that may, in the clinical judgement of the investigator, independently influence the subject’s outcome during this study, participation in another interventional clinical trial within the last four weeks
研究者
相似试验
已完成
2 期
Phase II Trial of Endocrine therapy for patients with Metastatic extramammary Paget's disease ExpRessing Androgen-Receptor using Darolutamide with/without LH-RH agonist.JPRN-jRCT2031220508akamura Yoshio40
进行中（未招募）
不适用
Trial of Perioperative Endocrine Therapy - Individualising Care (POETIC)EUCTR2007-003877-21-GBInstitute of Cancer Research
已完成
不适用
Scottish Post Menopausal Chemo-Endocrine TrialCancerBreast cancerISRCTN51555498Scottish Cancer Therapy Network (UK)
已完成
2 期
The effectiveness of endocrine disorders therapy in depression improvement of HIV infected meIRCT2013071914054N1vice chancellor for research of Tehran University of Medical Sciences104
进行中（未招募）
1 期
Early discontinuation of steroid treatment in negative FDG-PET/CT patients with idiopathic retroperitoneal fibrosisCTIS2024-514353-30-00Assistance Publique Hopitaux De Paris41